Pay in 4 interest-free payments of $7.33 Learn more
Ships within 48 hours · Estimated delivery Nov 6 - Nov 11
Monitoring should increase initially, often daily or multiple times per day, depending on the patients regimen
We interpret the clinical and mechanistic data obtained for different agents that enable weight loss and glucose control for the treatment of obesity and type 2 diabetes mellitus, respectively, by activating or blocking GIPR signalling, including the GIPRGLP1R co-agonist tirzepatide, as well as the GIPR antagonistGLP1R agonist AMG-133
Coverage also depends on whether your employer group included weight-loss drugs in the benefit design
Most patients qualify for therapy if they have a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related health condition such as type 2 diabetes, high blood pressure, high cholesterol, or sleep apnea
First, your BMI must meet minimum thresholds
US$ 21.71
US$ 28.32
US$ 29.55
US$ 22.97
US$ 20.02
